FDA-Approved Medicines and Compounded Preparations: Separate Evidence Questions

A telehealth page can name semaglutide, cite a major weight-loss trial and describe a compounded preparation in the same screen. Those statements may all concern related subjects, but they do not establish the same thing. For a U.S. adult considering care, the important distinction is between evidence about a specific medicine, documentation about the preparation actually prescribed and promises about the service arranging it. An ingredient name is a starting point for questions—not a bridge that automatically connects every claim.

FDA’s position requires two ideas to remain visible together: compounded preparations are not FDA approved, and FDA recommends them only when an individual’s medical needs cannot be met by an approved drug. Nonapproval alone does not prove clinical inequivalence. Nor does it establish equivalence. This guide uses public documentation from CoreAge Rx, Enhance.MD, Found, Ro, Sesame and Walgreens, consulted October 19, 2026, to show how those distinctions work. It does not independently verify their credentials, products or clinical outcomes.

At a glance

Approval is product-specific: FDA approval concerns a specific drug product, not the telehealth platform, clinic or pharmacy arranging access.
Sources: [1]
Individualized need matters: FDA recommends compounded drugs for patients whose medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy.
Sources: [1]
Nonapproval is not an equivalence study: Compounded preparations do not undergo FDA premarket review for safety, effectiveness and quality; that absence alone establishes neither clinical equivalence nor inequivalence.
Sources: [1]
Formulation details differ: CoreAge Rx says its compounded tirzepatide typically includes B-12; Enhance.MD markets an injectable combination of semaglutide and tirzepatide.
Sources: [17] [35]
Testing claims have a defined scope: Found states that its compounded semaglutide receives third-party testing for potency, purity and sterility before shipment. The consulted documentation does not identify that laboratory or provide certificates of analysis.
Sources: [21]

Start with the product, not the platform

The first question is what would actually be prescribed: a named branded product, a compounded preparation, an oral medicine or an injectable presentation. Ro’s documentation, for example, distinguishes an oral Wegovy pill from a Wegovy pen. Sesame describes Zepbound single-dose pens, multidose KwikPens and single-dose vials. These are useful product-identification details. They are not interchangeable descriptions of one generic service called “GLP-1 treatment,” and a provider’s catalogue is not itself independent confirmation of regulatory status.

Keep the business identity separate, too. Walgreens says independent medical practices control clinical care while Walgreens Health Services LLC supplies administrative services. Sesame identifies independently operated clinician practices and explicitly says it is not a pharmacy. Those disclosures help locate responsibility, but neither makes the platform FDA approved. A productive opening question is: “What exact product, formulation, route and presentation are you proposing, and which organization will prescribe and dispense it?”

Sources: [1] [18] [28] [13] [12] [9] [10]

Read FDA’s recommendation without adding a verdict

FDA says compounded preparations are not approved and do not undergo its premarket review for safety, effectiveness and quality. That is a material evidence limitation, not a semantic footnote. The agency recommends compounded drugs only for patients whose medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. This recommendation should remain attached to discussions of individualized compounding; it should not be rewritten as a categorical legal conclusion about every prescription.

Provider disclosures sometimes acknowledge this boundary directly. CoreAge Rx’s safety page distinguishes approved semaglutide products from compounded formulations. Enhance.MD’s Core page states that its compounded formulation is not FDA approved and describes availability by prescription for demonstrated clinical need. Found likewise discloses that compounded medicines are not FDA approved or evaluated by FDA for safety or efficacy. These disclosures document what the companies say. They do not, alone, establish whether a particular patient’s needs justify a particular preparation.

Sources: [1] [22] [8] [25]

Match each claim to the evidence that could answer it

Approval, trial efficacy, preparation testing and service performance are separate evidence categories. A published randomized trial can describe outcomes under its study conditions. A pharmacy test can address specified characteristics of a tested preparation. A company’s terms can identify who is responsible for prescribing. None automatically answers the other questions. The table below offers a practical way to sort a crowded sales page before evaluating whether its conclusions follow from the documents it cites.

This separation also prevents two opposite mistakes: treating every compounded preparation as proven equivalent because an ingredient has been studied, or treating nonapproval as proof that every preparation is clinically inferior. Neither inference is supported here. Ask for evidence at the level of the claim being made. Our guide to what public provider documents can prove explains why a detailed disclosure can be useful without becoming independent verification.

Different claims require different kinds of support
Question	Relevant documentation	What it does not establish
Is this product FDA approved?	Product-specific regulatory documentation	Approval of the clinic or pharmacy
What happened in a clinical trial?	Original study, population and intervention details	Results for this provider or an individual
What was tested in a preparation?	Identified testing methods and results	Clinical equivalence by itself
Who makes clinical decisions?	Medical-group and platform disclosures	Independent verification of credentials
How will problems be handled?	Follow-up, pharmacy and delivery policies	Guaranteed outcomes or immediate responses

Sources: [1] [3] [4]

Keep trial results inside their study boundaries

STEP 1 studied subcutaneous semaglutide in adults with obesity or overweight plus a weight-related condition, without diabetes, over 68 weeks, alongside lifestyle intervention. SURMOUNT-1 studied subcutaneous tirzepatide in adults with obesity or overweight plus a weight-related complication, excluding diabetes, over 72 weeks. Neither was a trial of the telehealth providers discussed here. The STEP 1 reading guide shows how population, route and study design constrain the conclusions a reader can draw.

Those limits become especially important when a page moves from an established ingredient to a different commercial protocol. CoreAge Rx markets both semaglutide and tirzepatide “Microdosing Therapy.” Found markets a compounded semaglutide microdosing program, while Enhance.MD markets tirzepatide microdosing. These offerings are documented; their names are not clinical validation. The trials do not establish results for microdoses, vitamin blends, other routes or these providers’ preparations. Nor should separate trials become a head-to-head ranking, as our SURMOUNT-1 guide explains.

Sources: [3] [4] [19] [20] [11] [32]

Ask what is in the preparation—and what was tested

CoreAge Rx says its compounded tirzepatide is typically formulated with B-12; someone seeking a version without B-12 is directed to discuss that request during intake with the provider. Enhance.MD’s Elite is marketed as an injectable formulation combining semaglutide and tirzepatide. These details matter because ingredient-level research does not automatically validate a blend. A claim of broader metabolic coverage or stronger appetite control remains the provider’s marketing unless evidence supports that particular conclusion for the preparation concerned.

Found states that it works exclusively with 503A compounding pharmacies and that its compounded semaglutide receives third-party potency, purity and sterility testing before shipment. Those are concrete claims worth asking about, but the consulted documentation does not name the laboratory or provide certificates. FDA also distinguishes semaglutide sodium and acetate from the active ingredient in approved drugs. Nothing here establishes that any named provider uses those salts; the useful response is to request the exact formulation, not infer its contents.

Sources: [1] [3] [4] [17] [35] [21]

Trace the clinician and pharmacy separately

The prescribing relationship is not necessarily with the company whose logo appears at checkout. CoreAge Rx assigns medical evaluation, planning and prescribing to three named independent professional entities and says its administrative business does not practice medicine. Enhance.MD similarly describes itself as an administrative platform supporting medical groups and says payment guarantees neither prescribing nor dispensing. These distinctions identify questions to resolve before enrollment: who reviews the history, who explains the proposed preparation and who remains responsible for clinical follow-up?

Pharmacy access also needs its own confirmation. CoreAge Rx’s FAQ requires its affiliated pharmacy network, while its terms allow a request for a pharmacy of the patient’s choosing before ordering. Enhance.MD permits an outside pharmacy but says medication costs are then billed separately; its FAQ and terms also list different pharmacy partners. Found says compounded medicines in its plan are filled through a pharmacy it facilitates. These are channel-specific arrangements, not evidence that the platform itself compounds or dispenses every medicine.

Sources: [24] [14] [17] [26] [16] [29] [25]

Treat follow-up as part of the evidence question

A documented care process does not establish efficacy, but it shows what support the provider promises. Ro lists individual provider messaging, regular check-ins, coaching and laboratory testing if necessary in its membership, with medication charged separately. Found describes monthly follow-up for compounded tirzepatide and messaging between visits for semaglutide. Enhance.MD says its Core subscription includes ongoing provider care and metabolic laboratory testing every six months. These are different service descriptions, not interchangeable guarantees of contact frequency or response speed.

NIDDK frames medicine selection around benefits, side effects, other medicines, health conditions, family history and cost; follow-up concerns response and tolerability, not just another payment. Ask who answers clinical questions and when. CoreAge Rx’s “24/7 Provider Support” heading is followed by text about customer support, while Walgreens’ round-the-clock pharmacy chat is distinct from clinician visits and may involve a wait. Neither establishes immediate prescriber access. For preparation, use the medical-claims checklist to separate service availability from clinical evidence.

Sources: [2] [6] [5] [21] [8] [30] [31]

Keep safety signals and delivery promises in proportion

FDA has received reports of measurement and administration errors involving compounded medicines, some associated with hospitalization. That supports asking the prescriber or pharmacist to clarify instructions; it does not support calculating a dose from an article. Adverse-event reports also lack a denominator for calculating a rate and do not automatically establish causation. They cannot become a provider-specific complication rate without appropriate evidence. Conversely, the absence of an event count in a company’s public pages is not evidence that no problems occurred.

Delivery claims answer another limited question. CoreAge Rx estimates arrival about two to three business days after pharmacy shipment, separate from review and preparation. Found says most members can start within a week, which is not a defined transit guarantee. Neither statement documents temperature control. FDA explicitly recommends not using an injectable GLP-1 medicine that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. Confirm that contact path before shipment rather than treating a speed claim as proof of acceptable handling.

Sources: [1] [7] [15]

Questions & answers

Does CoreAge Rx’s nonapproval disclosure mean its preparation is proven inferior?

No. Its disclosure establishes that compounded semaglutide lacks FDA approval and premarket review, not a finding of clinical inferiority. It also does not establish equivalence. Ask the treating clinician what individualized need the preparation addresses, what exact formulation is proposed and what evidence supports the claims being made for it.

Sources: [1] [22]

Does Found’s third-party testing claim establish clinical equivalence?

Not by itself. Found describes testing for potency, purity and sterility before shipment. That claim concerns specified preparation characteristics, not a comparative clinical outcome study. The consulted documentation does not provide certificates or identify the testing laboratory. Request the relevant documentation and keep testing claims separate from claims about expected weight loss.

Sources: [1] [21]

Can Enhance.MD’s Elite combination inherit both ingredients’ trial results?

The consulted trials do not establish outcomes for Elite’s combined semaglutide-and-tirzepatide formulation. Enhance.MD documents that it markets the combination, but its commercial description is not a trial of that product. Ask what preparation-specific evidence supports the proposed benefit rather than adding or combining results from separate studies.

Sources: [35] [3] [4]

Does Ro’s use of branded medicine establish Ro’s own effectiveness?

No. Ro’s documentation distinguishes named medicines and includes messaging, check-ins and coaching in its membership. Product evidence and service descriptions remain separate from measured outcomes of Ro’s care program. Eligibility is decided by a provider, and the membership does not include medication cost; neither enrollment nor payment guarantees a particular result.

Sources: [28] [6] [33] [3] [4]

What should a Sesame patient verify about pharmacy access?

Sesame says prescribed medication may be collected at a preferred local pharmacy or delivered, and its terms name Truepill as a delivery partner. Its Wegovy page directs readers to NovoCare for reduced cash pricing. Confirm the exact product and required pharmacy channel: a general pharmacy-choice statement does not mean every advertised access arrangement works through every pharmacy.

Sources: [34] [10] [27]

Is Walgreens’ 24/7 pharmacy chat the same as ongoing prescriber care?

No. Walgreens describes pharmacy-expert chat separately from weight-management follow-up visits. The chat may require waiting, is not for emergencies and does not replace physician advice. Its weight-management page lists follow-up clinician chat visits and additional video visits at $49 each. Chat availability alone establishes neither immediate prescriber access nor a zero fee.

Sources: [31] [23]

Our assessment

The strongest reading of these documents is neither blanket reassurance nor blanket rejection. Approved products have product-specific regulatory evidence; compounded preparations lack FDA premarket review and require a separate discussion of individualized need. Provider disclosures can identify formulations, responsible medical groups, pharmacy channels and promised follow-up, but they cannot substitute for preparation-specific clinical evidence. Before committing, obtain the exact proposed product, the clinician’s rationale, the dispensing pharmacy and a usable plan for questions or delivery problems. Where documentation conflicts or is unavailable, leave the question unresolved rather than filling the gap with a favorable—or unfavorable—assumption.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

FDA-Approved Medicines and Compounded Preparations: Separate Evidence Questions

At a glance

01Start with the product, not the platform

02Read FDA’s recommendation without adding a verdict

03Match each claim to the evidence that could answer it

04Keep trial results inside their study boundaries

05Ask what is in the preparation—and what was tested

06Trace the clinician and pharmacy separately

07Treat follow-up as part of the evidence question

08Keep safety signals and delivery promises in proportion